The use of monoclonal antibodies in measuring factor Vlll/von Willebrand factor

References

• Andersson L O, Brown J E. Interaction of factor VHI/von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161
   PubMed Web of Science ®Google Scholar
• Galfre G, Howe S C, Milstein C, Butcher G W, Howard J C. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 1977; 266: 550
   PubMed Web of Science ®Google Scholar
• Ganrot P O. Crossed Immunoelectrophoresis. Scand J Clin Lab Invest 1972; 29: 39
   Web of Science ®Google Scholar
• Goding J W. Antibody production by hybridomas. J Immunol Methods 1980; 39: 285
   PubMed Web of Science ®Google Scholar
• Holmberg L, Jeppsson J-O, Nilsson I M, Stenflo J. Cyanogen bromide and tryptic fragments of normal and haemophilic factor VIII. Thromb Res 1975; 6: 523
   PubMed Web of Science ®Google Scholar
• Holmberg L, Ljung R. Purification of F VIII:C by antigen-antibody chromatography. Thromb Res 1978; 12: 667
   PubMed Web of Science ®Google Scholar
• Holmberg L, Nilsson I M. Genetic variants of von Willebrandˆs disease. Br Med J 1972; 3: 317
   PubMedGoogle Scholar
• Holmberg L, Nilsson I M, Borge L, Gunnarsson M, Sjörin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type TIB von Willebrandˆs disease. N Engl J Med 1983; 309: 816
   PubMed Web of Science ®Google Scholar
• Kinoshita S, Harrison J, Lazerson J, Abildgaard C. A new variant of dominant type II von Willebrandˆs disease with aberrant multimeric structure of factor VHI-related antigen (VIIIRA). Thrombos Haemostas 1983; 50: 78, (abstract)
   Web of Science ®Google Scholar
• Lopez Fernandez M F, Ginsberg M H, Ruggeri Z M, Batlle F J, Zimmerman T S. Multimeric structure of platelet factor VHI/von Willebrand factor: The presence of larger multimers and their re-association with thrombin-stimulated platelets. Blood 1982; 60: 1132
   PubMed Web of Science ®Google Scholar
• van Mourik J A, Bouma B N, Labruyere W T, De Graaf S, Mochtar I A. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1974; 4: 155
   PubMed Web of Science ®Google Scholar
• Meyer D, Obert B, Zimmerman T, Edgington T. Monoclonal antibodies specific for factor VIII from cellular hybrids. Circulation 1980; 62((Suppl. III))106, (abstract)
   Google Scholar
• Nilsson I M. Haemorrhagic and thrombotic diseases. John Wiley & Sons, London 1974
   Google Scholar
• Nilsson I M, Meyer D, Hoyer L W, Ingram G IC, Rizza C R. Report of the subcommittee of factor VIII activities. Thrombos Haemostas 1980; 43: 163
   PubMed Web of Science ®Google Scholar
• Ogata K, Saito H, Ratnoff O D. The relationship of the properties of antihemophilic factor (factor VIII) that support ristocetin-induced platelet agglutination (factor VIII: RC) and platelet retension by glass beads as demonstrated by a monoclonal antibody. Blood 1983; 61: 27
   PubMed Web of Science ®Google Scholar
• Rotblat F, O'Brien D P, Middleton S M, Tuddenham E GD. Purification and characterisation of human VIILC. Thrombos Haemostas 1983; 50: 108, (abstract)
   Web of Science ®Google Scholar
• Ruggeri Z M, Lombardi R, Gatti L, Bader R, Valsecchi C, Zimmerman T S. Type IIB von Willebrandˆs disease: Differential clearance of endogenous versus transfused large multimer von Willebrand factor. Blood 1982; 60: 1453
   PubMed Web of Science ®Google Scholar
• Ruggeri Z M, Mannucci P M, Jeffcoate S L, Ingram G IC. Immunoradiometric assay of factor VIII related antigen with observations in 32 patients with von Willebrandˆs disease. Br J Haematol 1976; 33: 221
   PubMed Web of Science ®Google Scholar
• Ruggeri S M, Mannucci P M, Lombardi R, Federici A B, Zimmerman T S. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for pathophysiology and therapy of von Willebrandˆs disease subtypes. Blood 1982; 59: 1272
   PubMed Web of Science ®Google Scholar
• Ruggeri Z M, Nilsson I M, Lombardi R, Holmberg L, Zimmerman T S. Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrandˆs disease (type 1IC). J Clin Invest 1982; 70: 1124
   PubMedGoogle Scholar
• Ruggeri Z M, Zimmerman T S. Variant von Willebrandˆs disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318
   PubMed Web of Science ®Google Scholar
• Ruggeri Z M, Zimmerman T S. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140
   PubMed Web of Science ®Google Scholar
• Shulman M, Wilde D, Kohler G A. A better cell line for making hybridomas secreting specific antibodies. Nature 1978; 266: 269
   Google Scholar
• Stel H V, Sakariassen K S, Scholtc B J, Veerman E CI, van der Kwast T H, de Groot P G, Sixma J J, van Mourik J A. Characterization of twenty-five monoclonal antibodies to factor VHI-von Wille-brand factor. Relationship between ristocetin induced platelet aggregation and platelet adherence to subendothelium. Blood 1984; 63: 1408
   PubMed Web of Science ®Google Scholar
• Thorell J I, Larson S M. Radioimmunoassay and Related Techniques. Mosby Comp, St Louis 1978
   Google Scholar
• Zimmerman T S, Ruggeri Z M. von Willebrandˆs disease. Clin Haematol 1983; 12: 1–175
   PubMedGoogle Scholar
• Zuzel M, Nilsson I M, Aberg M. A method for measuring plasma ristocetin cofactor activity. Thromb Res 1978; 12: 745
   PubMed Web of Science ®Google Scholar